<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00272038</url>
  </required_header>
  <id_info>
    <org_study_id>OSI3652S (0513)</org_study_id>
    <nct_id>NCT00272038</nct_id>
    <nct_alias>NCT00321841</nct_alias>
  </id_info>
  <brief_title>Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer</brief_title>
  <official_title>Phase II Study Investigating the Efficacy and Activity of Single Agent Erlotinib in Chemotherapy-Naive Androgen Independent Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oncology Specialists, S.C.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oncology Specialists, S.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives to evaluate the activity of Erlotinib in prostate cancer patients who are hormone&#xD;
      refractory and androgen independent and have not been exposed to chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II open label single center study that evaluates the activity, efficacy, and&#xD;
      toxicity of single agent Tarceva in chemotherapy-naive AIPC patients. Patients will receive&#xD;
      single agent Tarceva at 150 mg daily without interruption until disease progression,&#xD;
      unacceptable toxicity, or investigator's discretion. Eligible patients are those with&#xD;
      documented prostate cancer (regardless of Gleason Score) who are considered hormone&#xD;
      refractory as defined below. All patients must fail an anti-androgen withdrawal trial if they&#xD;
      were already on such therapy. If patients were on LHRH analogues alone, they must fail the&#xD;
      addition of an anti-androgen before being classified as hormone refractory. All patients must&#xD;
      have adequate organ functions as specified below and have an ECOG performance status of 2 or&#xD;
      less. It is hypothesized that 25 patients will be needed to adequately assess the activity of&#xD;
      Tarceva in AIPC.&#xD;
&#xD;
      The activity of Tarceva in other malignancies has been demonstrated with dosed ranging from&#xD;
      100 to 150 mg daily. It is acceptable not to interrupt therapy unless toxicity occurs of&#xD;
      disease progression is documented. Starting patients at 150 mg daily seems to be the most&#xD;
      logical step, but dose reductions will be implemented based on side effects and adverse&#xD;
      events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Clinical Benefit of Tarceva in CRPC.</measure>
    <time_frame>5 years</time_frame>
    <description>Overall Clinical Benefit = percentage of partial responders (PR)+ the percentage of patients with stable disease (SD). Partial Response (PR) is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum. Stable Disease (SD)is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease, using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>during study</time_frame>
    <description>One year survival rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Progression</measure>
    <time_frame>25 months</time_frame>
    <description>Patients were evaluated for response biochemically and radiographically at each response assessment. RECIST 1.0 criteria were used for radiographic response. PSA measurement at a central laboratory was used to assess biochemical response. Patients must have had a baseline PSA of 5 ng/ml to be evaluated for PSA response. PSA was measured every 8 weeks.&#xD;
For patients with measurable disease radiographically, PSA progression was not considered as having progressive disease. Refer to study publication for details.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Tarceva</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tarceva 150 mg QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tarceva</intervention_name>
    <description>150mg QD</description>
    <arm_group_label>Tarceva</arm_group_label>
    <other_name>erlotinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented prostate cancer regardless of Gleason score&#xD;
&#xD;
          -  Patients should be considered hormone refractory and androgen independent. They must&#xD;
             fail LHRH analogues, and anti-androgen withdrawal trial.&#xD;
&#xD;
          -  Failure is confirmed by an increase in PSA value of 10% or more than the value&#xD;
             immediately before, and confirmed by another assessment 2 weeks later.&#xD;
&#xD;
          -  Patients have to have measurable disease either biochemically using rising PSA or/and&#xD;
             with metastatic disease to the bone or visceral organs.&#xD;
&#xD;
          -  Performance status of 2 or less using ECOG scale.Â· Adequate liver function tests with&#xD;
             ALT/AST being &lt; 3x normal, total bilirubin of 1.5 or less, and adequate renal function&#xD;
             measured by a creatinine of 2.0 mg/dl or less. Alkaline phosphatase values are never&#xD;
             exclusion criteria if it is deemed related to bone metastases.&#xD;
&#xD;
          -  Patients need to have adequate bone marrow function. ANC of 1000 or above, Hgb of 9.0&#xD;
             g/dl or above, and platelets of 100,000 or above. If other causes are affecting plts&#xD;
             counts such as autoimmune disorders, patients are allowed on study.&#xD;
&#xD;
          -  Patients with inadequate bone marrow function that is deemed related to bone marrow&#xD;
             involvement with prostate cancer are allowed at the investigator's discretion.&#xD;
&#xD;
          -  Patients with other malignancies are allowed as long as there is no evidence of the&#xD;
             other malignancy present at entry time, and it has been 3 years or more since the&#xD;
             treatment for the other disorder was completed.&#xD;
&#xD;
          -  Patients with prior exposure to investigational therapies including vaccines are&#xD;
             allowed on this study as long as their last exposure was 4 weeks prior to study&#xD;
             entry.Patients with known bone metastases are allowed to receive intravenous&#xD;
             bisphosphonates such as aredia or zometa.&#xD;
&#xD;
          -  Patients on oral bisphosphonates are also allowed.&#xD;
&#xD;
          -  Chemo Naive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with prior exposure to Tarceva&#xD;
&#xD;
          -  Patients who have received any prior systemic chemotherapy for prostate cancer.&#xD;
             Exposure to chemotherapy for other malignancies is allowed as long as last&#xD;
             chemotherapy was completed 3 years prior to study entry.&#xD;
&#xD;
          -  Patients with prior malignancies are excluded except for those who have non-melanoma&#xD;
             skin cancers or other cancers that are in remission with the last therapy given 3&#xD;
             years prior to enrollment.&#xD;
&#xD;
          -  Prior exposure to any form of steroids is allowed and is not considered exclusion&#xD;
             criteria.&#xD;
&#xD;
          -  Performance status of 3 or above using ECOG scale.&#xD;
&#xD;
          -  Known HIV positive status Known CNS involvement with prostate cancer&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chadi Nabhan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oncology Specialists, SC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oncology Specialists, SC</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>January 3, 2006</study_first_submitted>
  <study_first_submitted_qc>January 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2006</study_first_posted>
  <results_first_submitted>May 6, 2013</results_first_submitted>
  <results_first_submitted_qc>August 12, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 17, 2013</results_first_posted>
  <last_update_submitted>May 31, 2018</last_update_submitted>
  <last_update_submitted_qc>May 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oncology Specialists, S.C.</investigator_affiliation>
    <investigator_full_name>Dr. Sigrun Hallmeyer</investigator_full_name>
    <investigator_title>Sigrun Hallmeyer, MD Director of Research; Chadi Nabhan, MD Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eligible patients were those who met the criteria of Castration Resistant Prostate Cancer (CRPC)who had not yet received chemotherapy.</recruitment_details>
      <pre_assignment_details>Patients must have had adquate bone marrow function and, Eastern Cooperative Oncology Group (ECOG) &lt;3, and measurable disease.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tarceva</title>
          <description>Tarceva 150 mg orally every day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>withdrew before they received 2 cycles</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tarceva</title>
          <description>Tarceva 150 mg QD</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Clinical Benefit of Tarceva in CRPC.</title>
        <description>Overall Clinical Benefit = percentage of partial responders (PR)+ the percentage of patients with stable disease (SD). Partial Response (PR) is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum. Stable Disease (SD)is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease, using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0).</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tarceva</title>
            <description>Tarceva 150 mg QD</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Clinical Benefit of Tarceva in CRPC.</title>
          <description>Overall Clinical Benefit = percentage of partial responders (PR)+ the percentage of patients with stable disease (SD). Partial Response (PR) is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum. Stable Disease (SD)is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease, using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0).</description>
          <units>percentage of pts w/clinical benefit</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>One year survival rate.</description>
        <time_frame>during study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tarceva</title>
            <description>Tarceva 150 mg QD</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>One year survival rate.</description>
          <units>% of partcipants alive at one year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Disease Progression</title>
        <description>Patients were evaluated for response biochemically and radiographically at each response assessment. RECIST 1.0 criteria were used for radiographic response. PSA measurement at a central laboratory was used to assess biochemical response. Patients must have had a baseline PSA of 5 ng/ml to be evaluated for PSA response. PSA was measured every 8 weeks.&#xD;
For patients with measurable disease radiographically, PSA progression was not considered as having progressive disease. Refer to study publication for details.</description>
        <time_frame>25 months</time_frame>
        <population>29 participants enrolled. only 22 were evaluable, 4 withdrew consent, 2 had rapid PSA increase &amp; 1 had cord compression</population>
        <group_list>
          <group group_id="O1">
            <title>Tarceva</title>
            <description>Tarceva 150 mg QD&#xD;
Tarceva: 150mg QD</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Disease Progression</title>
          <description>Patients were evaluated for response biochemically and radiographically at each response assessment. RECIST 1.0 criteria were used for radiographic response. PSA measurement at a central laboratory was used to assess biochemical response. Patients must have had a baseline PSA of 5 ng/ml to be evaluated for PSA response. PSA was measured every 8 weeks.&#xD;
For patients with measurable disease radiographically, PSA progression was not considered as having progressive disease. Refer to study publication for details.</description>
          <population>29 participants enrolled. only 22 were evaluable, 4 withdrew consent, 2 had rapid PSA increase &amp; 1 had cord compression</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="NA">Not all participants experienced progression</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Tarceva</title>
          <description>Tarceva 150 mg QD</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastro Intestinal Bleed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Bowel Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Decompensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Involuntary Movement of Hands and Arms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Spinal Cord Compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pulmonary Emboli</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Alkaline Phosphatase High Grade 3 &amp; 4</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Elevated Grade 1 - 4</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Anemia Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Lymphopenia Grade 1 - 4</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Potassium Decreased Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Potassium Increased Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea Grade 3 &amp; 4</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Appetite decreased Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Calcium Low Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Constipation Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dehydration Grade 1 - 4</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Diarrhea Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Gastroesophageal Reflux Disease Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hyperglycemia Grade 1 - 4</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Mouth Sores Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Mouth Dry Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Protein Decreased Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Swallowing Difficulty Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Sodium Decreased Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Taste Change Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue Grade 3 &amp; 4</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Rash Grade 3 &amp; 4</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Chest Pain Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Chills Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Edema Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Fatigue Grade 1 - 4</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hematuria Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hot Flashes Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Libido decreased Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Eyes dry Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Eyes Watery Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Memory Loss Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia Grade 3 &amp; 4</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Fever Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Fungal Infection Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infection Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Headache Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Lightheadedness Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Insomnia Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Low Creatinine Grade 3 &amp; 4</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Anxiety Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Alkaline Phosphatase Increased Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Renal Insufficiency Grade 1 - 4</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Blood Urea Nitrogen increased Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Creatinine Increased Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dsynea on Exertion Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hemoptesis Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Wheezing Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand Foot Syndrome Grade 1 - 4</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hives Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Itching Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Nail changes Grade 1 &amp; 2</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Bruises easily</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sigrun Hallmeyer, MD (Director of Research); Chadi Nabhan, MD, FACP (PI)</name_or_title>
      <organization>Oncology Specialists, S.C.</organization>
      <phone>847-268-8200</phone>
      <email>shallmeyer@oncmed.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

